215 related articles for article (PubMed ID: 15768693)
1. [The world population does not have the drugs it needs. WHO report recommends more stringent control of the drug industry].
Asplund K
Lakartidningen; 2005 Feb 14-20; 102(7):450-1. PubMed ID: 15768693
[No Abstract] [Full Text] [Related]
2. TRIPS, pharmaceuticals, developing countries, and the Doha "solution".
Sykes AO
Chic J Int Law; 2002; 3(1):47-68. PubMed ID: 15709299
[No Abstract] [Full Text] [Related]
3. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
't Hoen E
Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
[No Abstract] [Full Text] [Related]
4. World pharmaceutical developments.
Bale H
World Hosp Health Serv; 2002; 38(2):1. PubMed ID: 12402745
[No Abstract] [Full Text] [Related]
5. Drug industry is considering more use of differential pricing, conference hears.
Sukkar E
BMJ; 2011 Dec; 343():d8049. PubMed ID: 22155726
[No Abstract] [Full Text] [Related]
6. Drug shortage crisis affects patients and nurses.
Carter D
Am J Nurs; 2011 Nov; 111(11):14. PubMed ID: 22030911
[No Abstract] [Full Text] [Related]
7. The responsibility of research universities to promote access to essential medicines.
't Hoen EF
Yale J Health Policy Law Ethics; 2003; 3(2):293-300. PubMed ID: 14577145
[No Abstract] [Full Text] [Related]
8. Drugs and vaccines around the world.
Health Aff (Millwood); 2006; 25(2):312. PubMed ID: 16522572
[No Abstract] [Full Text] [Related]
9. Medicine and the pharmaceutical industry.
Baxter P
Dev Med Child Neurol; 2006 Aug; 48(8):627. PubMed ID: 16836771
[No Abstract] [Full Text] [Related]
10. Innovation and the WHO's essential medicines list: giving credit where credit is due.
Wertheimer AI; Santella TM
Res Social Adm Pharm; 2007 Mar; 3(1):137-44. PubMed ID: 17350562
[No Abstract] [Full Text] [Related]
11. The GO License: only part of the solution.
Batson A; Milstien JB
Health Aff (Millwood); 2008; 27(1):140-2. PubMed ID: 18180489
[TBL] [Abstract][Full Text] [Related]
12. Access to essential drugs.
Dev World Bioeth; 2001 Nov; 1(2):89-92. PubMed ID: 12870517
[No Abstract] [Full Text] [Related]
13. A fair deal for the future: flexibilities under TRIPS.
So AD
Bull World Health Organ; 2004 Nov; 82(11):813. PubMed ID: 15640914
[No Abstract] [Full Text] [Related]
14. Deadlock on access to cheap drugs at global trade negotiations.
Hagmann M
Bull World Health Organ; 2003; 81(2):150-1. PubMed ID: 12751424
[No Abstract] [Full Text] [Related]
15. Access to medicines and global health: will Canada lead or flounder?
Orbinski J
CMAJ; 2004 Jan; 170(2):224-6. PubMed ID: 14734437
[No Abstract] [Full Text] [Related]
16. Drug companies should cut prices for developing countries, says G8 report.
Walgate R
Bull World Health Organ; 2003; 81(1):72-3. PubMed ID: 12640481
[No Abstract] [Full Text] [Related]
17. Global health challenges in the pharmaceutical world.
Abraham J
Health Econ Policy Law; 2009 Jan; 4(Pt 1):115-27. PubMed ID: 19099620
[No Abstract] [Full Text] [Related]
18. Impact of India's new patents law 2005: a physician's perspective.
Lele RD
J Assoc Physicians India; 2005 Aug; 53():671-5. PubMed ID: 16398073
[No Abstract] [Full Text] [Related]
19. Government action needed to step up research and development for world's most neglected diseases.
Pecoul B
Expert Rev Anti Infect Ther; 2005 Dec; 3(6):841-3. PubMed ID: 16307495
[No Abstract] [Full Text] [Related]
20. The morally uncomfortable global drug gap.
Cohen-Kohler JC
Clin Pharmacol Ther; 2007 Nov; 82(5):610-4. PubMed ID: 17898710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
